European partnership fostering a European Research Area (ERA) for health research (Phase 2)
The European partnership fostering a European Research Area (ERA) for health research (ERA4Health) Phase 2 offers substantial funding for large-scale, multi-country Investigator-Initiated Clinical Studies (IICS). This initiative aims to enhance the efficiency of health research across the EU and Associated Countries, providing a streamlined mechanism for multinational collaborations in critical public health areas and complementing existing research efforts under Horizon Europe.
Who is Funded
This program targets the existing ERA4Health consortium, allowing for the expansion to include new partners such as public funders, philanthropic organizations, and even entities from the United States. Its goal is to enhance health research and reduce disease burden across the European Research Area and beyond.
What is Funded
This program funds health research with a strong focus on clinical studies and public health interventions. It supports a wide range of medical fields, from cardiovascular health to infectious diseases and mental disorders, including the development of new technologies and personalized care pathways. Eligible costs cover direct project activities and financial support to third parties, with a specific focus on late-stage clinical development.
Type and Scope of Funding
The ERA4Health Phase 2 provides grant funding with a significant EU contribution, primarily supporting Investigator-Initiated Clinical Studies. The funding rate is 30% of eligible costs, and financial support to third parties is a key component, with a maximum of 10,000,000 € per third party. Projects under this phase can run for up to nine years.
Conditions and Requirements
Applicants must adhere to specific conditions regarding proposal submission, consortium structure, and budget allocation. A key requirement is the continuation of an existing consortium, with clear stipulations on funding allocation for Investigator-Initiated Clinical Studies. Special attention is given to gender considerations, the integration of Social Sciences and Humanities expertise, and international cooperation, while restricting participation from high-risk suppliers in communication networks.
Application Procedure
The application process requires the coordinator of the existing ERA4Health consortium to submit a proposal through a single-stage submission process. Proposals are evaluated based on specific criteria for excellence, impact, and implementation, with successful applications leading to an amendment of the current grant agreement.
Legal Basis
The ERA4Health Phase 2 partnership is legally founded on the Horizon Europe Regulation, complemented by specific program decisions and financial regulations that detail its operational framework. All governing documents are publicly accessible via the European Commission's official portals.
Similar Programs
Funding Overview
Funding Status:
Closed
Maximum Amount:
77,000,000 €
Allocated Budget:
77,000,000 €
Deadline:
03.06.2025
Open Until:
03.06.2034
Award Channel:
Framework Programme Call
Region:
European Union and Associated Countries, with specific eligibility for the United States of America. International cooperation, including with non-European institutions, is encouraged.
Sectors:
Healthcare, Research and Development, Medical Technology, Pharmaceutical Industry
Application Type:
Consortium Required
Funding Stages:
Applied Research, Experimental Development, Pilot Testing, Prototyping, Commercialization, Implementation, Service Delivery, Monitoring
Funding Provider
Program Level:
European Union
Funding Body:
European Commission
Additional Partners:
European Clinical Research Infrastructure Network (ECRIN), Biobanking and Biomolecular Resources Research Infrastructure (BBMRI). The partnership also involves Ministries in charge of R&I and health/care policy, national and regional R&I and technology funding agencies and foundations, health and care authorities, organisations, and providers.
Website: